Is Teva Pharmaceutical Industries Limited (NYSE:TEVA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Teva Pharmaceutical Industries Limited at current levels.
Teva's AUSTEDO franchise and debt paydown are engineering a generics giant's metamorphosis into a specialty pharma story at half the price.
Where TEVA is headed
Something strange is happening at Teva. A company that spent a decade synonymous with overleveraged generics decline is now throwing off $2.6 billion in free cash flow, growing AUSTEDO into a blockbuster neuroscience franchise, and trading at 11x forward earnings while its stock has more than doubled off 2024 lows. By late 2027, Teva could be generating north of $4 billion in revenue from its innovative portfolio alone — AUSTEDO for tardive dyskinesia and Huntington's chorea approaching $3 billion in peak sales, AJOVY holding steady in the competitive migraine space, and UZEDY carving out a meaningful niche in long-acting injectable schizophrenia treatment. The generics business, still the majority of revenue, won't grow much — but it doesn't need to. It's the cash engine funding the transformation.
Read the full Compass Direction on TEVA
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $34.07).
See the full TEVA analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Teva Pharmaceutical Industries Limited (NYSE:TEVA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Teva Pharmaceutical Industries Limited at current levels. Teva's AUSTEDO franchise and debt paydown are engineering a generics giant's metamorphosis into a specialty pharma story at half the price.
What is TEVA's Compass Score?
Teva Pharmaceutical Industries Limited scores 52/100 on Alexandria's Compass, placing it in the "Neutral" tier. Scores blend eight factors and update weekly.
What is the price target for TEVA?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the TEVA page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.